Research of New Biomarker for Breast Cancer Using Proteomic Patterns.
10.4048/jkbcs.2004.7.1.22
- Author:
Yong Sik JUNG
1
;
Ho Seung KIM
;
Tae Il YOON
;
Mi Seon JEON
;
Yong Dal YOON
;
Yong Sung LEE
;
Ki Whan LEE
;
Hye Jin KIM
;
Myung Wook KIM
;
Hee Boong PARK
Author Information
1. Department of Surgery, Ajou University School of Medicine, Korea. dr@pabc.net
- Publication Type:Original Article
- Keywords:
Breast cancer;
Proteomics;
SELDI-TOF
- MeSH:
Biomarkers;
Breast Neoplasms*;
Breast*;
Delivery of Health Care;
Female;
Humans;
Hydrophobic and Hydrophilic Interactions;
Mass Screening;
Protein Array Analysis;
Proteomics;
Sensitivity and Specificity
- From:Journal of Korean Breast Cancer Society
2004;7(1):22-26
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Early detection and treatment of cancer is a primary focus of health care. Many serum markers are available for breast cancer, but are not good enough for screening. Cancer antigen CA 15-3 is the most widely used biomarker for breast cancer. However, CA 15-3 has low sensitivity and specificity. This study was performed to analyze the serum proteomic pattern in breast cancer patients by surface-enhanced laser desoption/ionization time- of-flight (SELDI-TOF). METHODS: We screened for potential tumor biomarkers in 42 serum samples, including samples from a group of 23 breast cancer patients at different clinical stages [stage I (n=3), stage II (n=11), stage III (n=6), and stage IV (n=1)], and a control group of 19 healthy women. Diluted serum samples were applied to a C16 hydrophobic interaction chip (H4). Complex protein profiles of different groups were compared and analyzed using the Protein Chip software 2.1 (Ciphergen Biosystems). RESULTS: There were 7 significant protein peaks in the breast cancer group and 5 in the control group. Scoring the expression of each peak, the mean score was 8.5 in the cancer group and 3.5 in the control. The results of the combination of each peak were highly sensitive (91.2%) and specific (94.7%). These proteomic patterns did not correlate with tumor stage and hormonal receptor, c-erb B2. CONCLUSION: In this preliminary report, we identified protein profiles that were differentiated in breast cancer patients. After proper validation, serum proteomic pattern analysis may ultimately be applied in screening breast cancer as a stand-alone or combined with current options.
